A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo [1 ]
Couriel, Daniel R. [2 ]
Tambaro, Francesco Paolo [1 ]
Gabrail, Nashat [3 ]
Nadeem, Ahmed [4 ]
Kadia, Tapan [1 ]
Jabbour, Elias [1 ]
Borthakur, Gautam [1 ]
Faderl, Stefan [1 ]
Newsome, Willie [1 ]
Yang, Hui [1 ]
Chen, Kevin [5 ]
Stein, Karen [5 ]
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] No Rhode Isl Hematol Oncol Program, Woonsocket, RI USA
[5] Eisai & Co Ltd, Woodcliff Lake, NJ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [1] Preliminary results of a phase II study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome (MDS)
    Steensma, David P.
    Baer, Maria R.
    Slack, James L.
    Buckstein, Rena
    Godley, Lucy
    Larsen, Julie S.
    Cullen, Michael T.
    Kantarjian, HaIgop M.
    BLOOD, 2007, 110 (11) : 434A - 435A
  • [2] Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
    Jabbour, Elias
    Short, Nicholas J.
    Montalban-Bravo, Guillermo
    Huang, Xuelin
    Bueso-Ramos, Carlos
    Qiao, Wei
    Yang, Hui
    Zhao, Chong
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Sasaki, Koji
    Estrov, Zeev
    Cortes, Jorge
    Ravandi, Farhad
    Alvarado, Yesid
    Komrokji, Rami
    Sekeres, Mikkael A.
    Steensma, David P.
    DeZern, Amy
    Roboz, Gail
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2017, 130 (13) : 1514 - 1522
  • [3] Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Sasaki, Koji
    Daver, Naval
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Kadia, Tapan
    Miller, Darla
    Sukholutsky, Victoria
    Huang, Xuelin
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [4] A RANDOMIZED STUDY OF DECITABINE ALTERNATING WITH CLOFARABINE VERSUS DECITABINE ALONE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Faderl, S.
    Garcia-Manero, G.
    Kadia, T.
    Borthakur, G.
    Jabbour, E.
    Ravandi, F.
    Estrov, Z.
    Cortes, J.
    Autry, J.
    Kantarjian, H.
    HAEMATOLOGICA, 2012, 97 : 369 - 369
  • [5] A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients.
    Wijermans, P
    Lübbert, M
    Verhoef, G
    Bosly, A
    Ravoet, C
    Andre, M
    Ferrant, A
    BLOOD, 1998, 92 (10) : 632A - 632A
  • [6] A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
    Jabbour, Elias J.
    Short, Nicholas J.
    Huang, Xuelin
    Maiti, Abhishek
    Kadia, Tapan M.
    Daver, Naval
    Borthakur, Gautam
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Sasaki, Koji
    Estrov, Zeev
    Verstovsek, Srdan
    Ravandi, Farhad
    Alvarado, Yesid
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Miller, Darla
    Dong, Xiao
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
  • [7] Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients.
    Raza, Azra
    Mukherjee, Siddhartha
    Eisenberger, Andrew
    Mears, J. Gregory
    Wilhelm, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase II study of low dose CPT-11 administered three times weekly in fluorouracil refractory patients with metastatic colorectal cancer.
    Shinozaki, E
    Mizunuma, N
    Nagasaki, E
    Horikoshi, N
    Muto, T
    Takahashi, Y
    Hatake, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 298S - 298S
  • [9] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
    Lyons, Roger M.
    Larson, Richard A.
    Kosmo, Michael A.
    Gandhi, Sunil
    Liu, Delong
    Chernoff, Marc
    Dreisbach, Luke
    Matei, Carmen
    Hu, Kuolong
    Franklin, Janet L.
    Berger, Dietmar
    BLOOD, 2009, 114 (22) : 703 - 704
12345